Doctor’s Guide -- MILAN, Italy -- October 10, 2010 -- Incorporating bevacizumab into standard first-line chemotherapy and maintenance treatment significantly improves progression-free survival (PFS) in patients with ovarian cancer, with no cumulative toxicity.
